Tesamorelin 5mg

Tesamorelin is an FDA-approved peptide used to treat lipodystrophy, a condition characterized by abnormal fat distribution, particularly in the abdomen. It is a synthetic analog of growth hormone-releasing hormone (GHRH), which stimulates the pituitary gland to release growth hormone (GH). This increase in GH plays a crucial role in fat reduction, muscle growth, and overall body composition improvement.

How Tesamorelin Works

Tesamorelin stimulates the release of GH, which, in turn, raises levels of insulin-like growth factor 1 (IGF-1). IGF-1 promotes muscle growth, fat loss, and tissue repair. Tesamorelin’s fat-burning effects are especially evident in reducing visceral fat, making it beneficial for those seeking to improve body composition or enhance physical performance.

Key Benefits of Tesamorelin

• Fat Reduction:
  Tesamorelin is primarily used for fat reduction, especially visceral abdominal fat. It has been shown to reduce visceral fat by up to 18% in HIV-infected patients with lipodystrophy. It works by increasing adiponectin, a protein that helps break down fat, leading to a significant reduction in abdominal fat.

• • Studies: Tesamorelin treatment for 26-52 weeks resulted in sustained reductions in visceral fat and improved body image in HIV patients. [1-7]

• Cognitive Function:
  Tesamorelin has cognitive-enhancing properties, improving memory and executive function in older adults and those with mild cognitive impairment.

• • Studies: In clinical trials, tesamorelin improved verbal memory and executive function in both healthy older adults and those with mild cognitive impairment. [10-17]

• Lipid Profile Improvement:
  Tesamorelin improves lipid profiles, reducing triglycerides, total cholesterol, and bad cholesterol (LDL), while raising good cholesterol (HDL).

• • Studies: Significant improvements in lipid levels were observed in HIV patients, with reductions in triglycerides and total cholesterol. [1, 9, 20-23]

• Liver Health:
  Tesamorelin reduces liver fat and improves liver function, particularly in HIV-infected individuals with hepatic steatosis (fatty liver).

• • Studies: Treatment reduced liver fat and improved liver enzyme levels in HIV patients. [24-26]

• Blood Sugar Regulation:
  Tesamorelin helps lower blood sugar levels by promoting fat loss, which can benefit patients with metabolic syndrome or type 2 diabetes.

• • Studies: In HIV patients, tesamorelin treatment reduced blood sugar and improved metabolic markers. [9, 27]

• Cardiovascular Health:
  By improving lipid profiles and raising HDL cholesterol, tesamorelin may lower the risk of cardiovascular diseases.

• • Studies: An increase in HDL levels and a decrease in total cholesterol can significantly reduce cardiovascular risk. [21, 28]

• Nerve Injury Repair:
  Tesamorelin shows promise in speeding up nerve healing, particularly after nerve injury.

• • Studies: Growth hormone therapies like tesamorelin may accelerate nerve regeneration. [29]

Side Effects of Tesamorelin

Tesamorelin is generally well-tolerated, though some side effects may occur, including:

• Common Effects:
  • Difficulty breathing
  • Dizziness
  • Swelling of the face or throat
  • Elevated blood sugar levels
  • Fast heartbeat
  • Joint pain
  • Night sweats
  • Rash, hives, or itching
  • Vomiting

Side effects are typically mild and may resolve with continued use. Always consult with a healthcare provider before starting treatment.

Tesamorelin Tablets

Tesamorelin tablets offer a convenient alternative to injectable forms, allowing for easier administration and better patient compliance. Like the injectable version, Tesamorelin tablets stimulate the release of GH, promoting fat loss and improving body composition. Clinical studies suggest that Tesamorelin tablets effectively reduce excess abdominal fat in individuals with HIV-related lipodystrophy, improving metabolic health and overall well-being.

Conclusion

Tesamorelin is a potent peptide therapy with significant benefits, including fat loss, cognitive enhancement, improved lipid profiles, and better liver and cardiovascular health. While primarily used for reducing visceral fat in HIV patients, its broad therapeutic potential makes it valuable for a range of conditions, including metabolic syndrome and cognitive decline. Always consult a healthcare provider to determine if Tesamorelin is right for you.

References

1. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28.
2. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune DeficSyndr. 2010;53(3):311-22.
3. Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011;3:69–79. doi:10.2147/HIV.S14561.
4. Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-8.
5. Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015;10(10):e0140358. Published 2015 Oct 12. doi:10.1371/journal.pone.0140358.
6. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J ClinEndocrinolMetab. 2010;95(9):4291-304.
7. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
8. Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54:1642–1651.
9. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9.
10. Mclarnon A. Neuroendocrinology: Tesamorelin can improve cognitive function. Nat Rev Endocrinol. 2012;8(10):568.
11. Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27:318-323.
12. Baker LD, Vitiello MV. Growth hormone-releasing hormone improves cognitive function in older adults: sleep on it–reply. JAMA Neurol. 2013;70(4):529-30.
13. Baker, L. D. et al. Effects of growthhormone-releasing hormone on cognitive function in adultswith mild cognitive impairment on healthy older adults.Arch. Neurol. doi:10.1001/archneurol.2012.1970.
14. Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-890. doi:10.1001/jamaneurol.2013.1425.
15. Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. Published 2017 Jun 15. doi:10.1371/journal.pone.0179538.
16. Maggi P, Di biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017;17(1):551.
17. Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10. PMID: 22495074; PMCID: PMC3348954.
18. Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253–2259. doi:10.1097/QAD.0000000000001614.
19. Miller K, Halow J, Koretsky AP. Phosphocreatine protects transgenic mouse liver expressing creatine kinase from hypoxia and ischemia. Am J Physiol. 1993;265(6 Pt 1):C1544-51.
20. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-7.
21. Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol–current therapies and future opportunities. Br J Pharmacol. 2012;167(6):1177–1194. doi:10.1111/j.1476-5381.2012.02081.x.
22. Tuffaha SH, Singh P, Budihardjo JD, et al. Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert OpinTher Targets. 2016;20(10):1259-65.